Viva Biotech is transforming the landscape of drug metabolism and pharmacokinetics (DMPK) with its innovative platform that seamlessly integrates various modalities. This one-stop pharmacology service not only streamlines the drug development process but also enhances the efficiency and reliability of pharmacokinetic studies across diverse therapeutic areas.
Comprehensive PK Design for Peptides
In the realm of peptide development, Viva Biotech excels in cross-species pharmacokinetic (PK) design. The platform supports multiple administration routes, including subcutaneous (SC), intravenous (IV), and intramuscular (IM) injections. By employing WinNonlin-based analysis consistently across these modalities, Viva facilitates comprehensive metabolite profiling, which encompasses plasma, urine, bile, feces, and various tissues. This uniform analytical framework allows for meaningful comparisons of peptide PK behaviors alongside small-molecule programs, enhancing the understanding of their pharmacological profiles.
Advancements in Antibody Pharmacokinetics
Viva Biotech extends its robust ADME-PK foundation to antibody programs, where understanding the biology of the neonatal Fc receptor (FcRn) is crucial. A significant technical advancement is the development of the engineered hFcRn/B2M-MDCK Transwell system, which provides a novel approach to studying antibody transcytosis. This system generates a cellular readout of FcRn-mediated transport, allowing for precise measurements of time- and dose-dependent transcytosis. These insights are invaluable for evaluating Fc-engineering variants, such as YTE and LALA Fc, along with Fc fusion proteins. Importantly, recent data indicate a strong correlation between the cell-based transcytosis readouts and published clinical antibody half-life data, underscoring the system’s potential for early candidate ranking before in vivo studies commence.
Integrating Mechanistic Bioassays
The synergy between DMPK decisions and mechanistic bioassays enhances the actionable insights that can be derived from pharmacological data. Viva Biotech’s immunology in vitro portfolio encompasses a range of assays focused on immune-cell activation, differentiation, and signaling. With capabilities that include multi-color flow cytometry, multiplex cytokine profiling, reporter assays, and Incucyte imaging systems, Viva provides a comprehensive toolkit for understanding immune responses.
On the in vivo front, Viva Biotech has established tumor efficacy evaluation capabilities that span syngeneic and patient-derived xenograft (CDX) models. Ex vivo analyses further support the assessment of tumor-infiltrating lymphocytes (TIL), pharmacodynamic biomarkers, and pathology readouts. This integrated approach allows for a holistic evaluation of drug exposure, target engagement, and functional outcomes within relevant disease contexts.
Decade-Long Expertise in Drug Discovery
With over a decade of experience in early drug discovery, Viva Biotech has cultivated a comprehensive suite of DMPK, pharmacology, and efficacy capabilities. The recent expansion of facilities and deeper integration of antibody pharmacokinetics with disease-focused studies across oncology, autoimmune disorders, and metabolic diseases have significantly strengthened this foundation. Dr. Cui articulates that Viva Biotech has successfully established a comprehensive DMPK platform that encompasses multiple drug modalities. This platform is embedded within a one-stop service model that connects structure-based discovery with ADME processes, pharmacokinetics, pharmacology, toxicology, and IND filing support, promoting more confident and data-driven development decisions throughout the preclinical stage.
Future Directions in DMPK and Pharmacology
As Viva Biotech continues to innovate and expand its offerings, the focus remains on enhancing the integration of pharmacokinetic studies with therapeutic development. The ongoing commitment to advancing methodologies and leveraging cutting-edge technologies will undoubtedly contribute to more effective drug discovery processes and improved patient outcomes.
- Key Takeaways:
- Viva Biotech offers comprehensive PK design across peptide and antibody programs.
- The hFcRn/B2M-MDCK Transwell system enhances understanding of antibody transcytosis.
- Mechanistic bioassays strengthen the connection between DMPK decisions and pharmacological outcomes.
- A decade of experience informs Viva’s innovative approach to DMPK and drug discovery.
- The integrated platform facilitates more confident preclinical development decisions.
In conclusion, Viva Biotech stands at the forefront of DMPK innovation, offering a holistic and efficient platform that bridges various aspects of pharmacology. This comprehensive approach not only enhances the drug development process but also positions Viva as a leader in the biotech industry, ready to tackle the challenges of modern pharmacology.
Source: www.manilatimes.net